Everolimus is a Oral Tablet, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Mylan Pharmaceuticals Inc.. The primary component is Everolimus.
| Product ID | 0378-0007_ca1a987e-f763-4026-93c5-c545ca95826c |
| NDC | 0378-0007 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Everolimus |
| Generic Name | Everolimus |
| Dosage Form | Tablet, For Suspension |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-10-01 |
| Marketing Category | ANDA / |
| Application Number | ANDA210130 |
| Labeler Name | Mylan Pharmaceuticals Inc. |
| Substance Name | EVEROLIMUS |
| Active Ingredient Strength | 5 mg/1 |
| Pharm Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Decreased Immunologic Activity [PE] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-10-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0054-0470 | Everolimus | Everolimus |
| 0054-0471 | Everolimus | Everolimus |
| 0054-0472 | Everolimus | Everolimus |
| 0054-0480 | Everolimus | Everolimus |
| 0054-0481 | Everolimus | Everolimus |
| 0054-0497 | Everolimus | Everolimus |
| 49884-119 | Everolimus | Everolimus |
| 49884-127 | Everolimus | Everolimus |
| 49884-125 | Everolimus | Everolimus |
| 0378-3098 | everolimus | everolimus |
| 0093-7766 | Everolimus | Everolimus |
| 0378-3097 | everolimus | everolimus |
| 0093-7767 | Everolimus | Everolimus |
| 0093-7768 | Everolimus | Everolimus |
| 0378-3096 | everolimus | everolimus |
| 0078-0566 | Afinitor | everolimus |
| 0078-0567 | Afinitor | everolimus |
| 0078-0594 | Afinitor | everolimus |
| 0078-0414 | Zortress | everolimus |
| 0078-0415 | Zortress | everolimus |
| 0078-0417 | Zortress | everolimus |
| 0078-0422 | Zortress | everolimus |